Investigational Drug Information for Molnupiravir
✉ Email this page to a colleague
What is the drug development status for Molnupiravir?
Molnupiravir is an investigational drug.
There have been 18 clinical trials for Molnupiravir.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 11th 2021.
The most common disease conditions in clinical trials are COVID-19, Coronavirus Infections, and Influenza, Human. The leading clinical trial sponsors are Merck Sharp & Dohme LLC, Ridgeback Biotherapeutics, LP, and Merck Sharp & Dohme Corp.
Summary for Molnupiravir
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 6 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2021-08-11) |
| Vendors | 44 |
Recent Clinical Trials for Molnupiravir
| Title | Sponsor | Phase |
|---|---|---|
| MG Granules Improve COVID-19 Efficacy and Safety of Convalescent Exercise Tolerance | Hangzhou Hospital of Traditional Chinese Medicine | N/A |
| MG Granules Improve COVID-19 Efficacy and Safety of Convalescent Exercise Tolerance | Suzhou Hospital of Traditional Chinese Medicine | N/A |
| MG Granules Improve COVID-19 Efficacy and Safety of Convalescent Exercise Tolerance | The First Affiliated Hospital of Zhejiang Chinese Medical University | N/A |
Clinical Trial Summary for Molnupiravir
Top disease conditions for Molnupiravir
Top clinical trial sponsors for Molnupiravir
US Patents for Molnupiravir
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
